
    
      A randomised double-blind study to assess the efficacy of selumetinib (AZD6244, Hyd-Sulfate)
      in combination with Dacarbazine compared with placebo in combination with Dacarbazine as
      first systemic therapy in patients with metastatic uveal melanoma (SUMIT)
    
  